Hims & Hers Health: Gobble Up Shares While You Can

Nov. 09, 2022 3:41 PM ETHims & Hers Health, Inc. (HIMS)14 Comments
Raul Shah profile picture
Raul Shah


  • Hims posted another excellent quarter with record-breaking subscriptions and revenue. AOV, Retention Rates, and Churn Rates are all at impressive levels.
  • Management delivered on its promises to scale up the business while providing great customer satisfaction. Multi-month subscriptions are increasing, resulting in more customer stickiness.
  • The company expects to be EBITDA positive for the first time in its history next quarter. I expect free cash flow to be positive by 2025.
  • I believe the stock's fair price is around $17-$18, representing over a 200% gain from current levels.

Senior Asian woman having a virtual appointment with doctor online, consulting her prescription and choice of medication on smartphone at home. Telemedicine, elderly and healthcare concept


Hims & Hers Health (NYSE:HIMS) has been my biggest position and most written about stock over the past year.

Company Background

Hims is a telehealth company which connects patients to licensed physicians for a range of medical issues, such as: sexual

HIMS Quarterly Subscriptions and Revenue Growth

Quarterly Subscriptions and Revenue Growth (HIMS Q3 Presentation)

Hims 2022 Revenue Forecast Wall Street

HIMS 2022 Revenue Forecasts (DocShah Capital)

DocShah's Hims Revenue Forecasts

My Previous Revenue Forecasts (DocShah Capital)

HIMS Discounted Cash Flow

HIMS Discounted Cash Flow (DocShah Capital)

This article was written by

Raul Shah profile picture
Raul Shah is a current player for MLB in the World Baseball Classic and Minor League player who has been featured in Forbes as one of America's best stock pickers. He is ranked in the top 1% in TipRanks and is labeled "The Hardest Working Man in Professional Baseball." He graduated from The Johns Hopkins University with a degree in Economics and Finance. He is the son of a physician and computer programmer.

Disclosure: I/we have a beneficial long position in the shares of HIMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Neither this article nor any comment, message, video, or interaction associated with it is to be taken as financial advice. Investors should always do their own research before executing any financial transaction. Raul Shah is not liable for any financial outcome which might occur. Investors assume full responsibility for their actions.

Recommended For You

Comments (14)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.